INS and Hypoglycemia: This association between basal insulin and prandial GLP-1 receptor agonists is preferred today to the classical intensification of basal insulin therapy by adding prandial insulins, as it offers advantages of both a lower risk for hypoglycemia and a reduced weight gain [88, 89].